Secondary analyses of the STO-3 trial have indicated that the70-gene signature and Breast Cancer Index multigene tests may help in selecting node-negative, postmenopausal ER+ HER- breast cancer patients for whom limited or no adjuvant tamoxifen would suffice [13, 33]. This evidence concerns the gene ESR1 and breast carcinoma.